- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02723604
Low-Level Laser Therapy for Prevention of Oral Mucositis
A Phase II Prospective Trial of Low-Level Laser Therapy for Prevention of Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Study Overview
Detailed Description
A phase II, single-arm trial to examine the efficacy of prophylactic low-level laser therapy (LLLT) to reduce the incidence of oral mucositis and adverse events in patients receiving combined modality therapy consisting of chemotherapy and radiation therapy for head and neck cancer.
Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
Patients will be evaluated prior to therapy, weekly during therapy, two weeks after the completion of therapy, and three months after the completion of therapy. During each assessment, the following toxicities will be assessed: pain, mucositis, dysphagia, xerostomia, dysgeusia, dermatitis, trismus, and quality of life.
Previous studies indicate that approximately 40% of patients will experience severe mucositis with radiation and concurrent chemotherapy. The hypothesis in this trial is that the addition of LLLT to this treatment regimen will decrease the rate of severe acute oral mucositis (OM) to 20%. We plan to enroll 25 patients at our institution in 12 months after the trial opens.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Wayne State University/Karmanos Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to understand and sign informed consent form approved by the institutional review board (IRB)
- Males or females greater than or equal to 18 years old
- Biopsy-proven head and neck cancer (HNC) including cancers of the nasopharynx, oropharynx, larynx, hypopharynx, or HNC of unknown primary origin amenable to therapy with radiation and concurrent chemotherapy
- Patients who are planned to receive definitive or adjuvant radiotherapy with concurrent platinum-based chemotherapy
- Patients whose clinical treatment plans include a continuous course of external beam radiotherapy by intensity-modulated radiation therapy (IMRT) and/or image-guided radiation therapy (IGRT), given as a cumulative dose of 5000 - 7000 centigray (cGy) in single daily fractions of 180 - 200 cGy, combined with a concurrent course of weekly or tri-weekly cisplatin or carboplatin chemotherapy
- Karnofsky performance status score > 60
- Female patients of child-bearing potential must have a negative pregnancy test prior to enrollment
Exclusion Criteria:
- Patient has evidence of current mucositis, mucosal ulceration, or unhealed surgical wounds from surgical resection or biopsy
- Prior radiation to the head and neck
- Patients with gross tumor involvement of the oral cavity or oral mucosa
- Patient planned to receive altered fractionation radiotherapy or multiple fractions per day
- Patient is using a pre-existing feeding tube for nutritional support at the time of study entry
- Women who are pregnant or breast-feeding
- Patient plans to receive concurrent chemotherapy, other than the regimens specified in the inclusion criteria
- Patients who have chronic immunosuppression or are on current immunosuppressive therapies
- Patients who have a contraindication to radiation therapy
- Patients enrolled on another investigational trial for oral mucositis prevention
- Life expectancy of less than 3 months
- Unable or unwilling to adhere to study-specified procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: Low Level Laser Therapy
Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy.
The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
|
Patients will receive LLLT three times per week concurrently with chemoradiotherapy.
LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy.
Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate.
During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis.
If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis.
The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Severe (Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v. 4.0] Grade 3-5 Oral Mucositis in Patients Treated to a Cumulative Radiation Dose of at Least 5000 cGy
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
From beginning of therapy up to 3 months after completion of therapy
|
Number of Participants With Severe World Health Organization [WHO] (Grade 3-4) Oral Mucositis in Patients Treated to a Cumulative Radiation Dose of at Least 5000 cGy
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
From beginning of therapy up to 3 months after completion of therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in OM-related QOL Assessed Using FACT Questionnaire
Time Frame: From beginning of therapy up to completion of therapy
|
The QOL assessment taken at the beginning of therapy is subtracted from the QOL assessment taken at the completion of therapy.
The QOL scale is the FACT Questionnaire.
Measure on a scale of 0 to 4. 0 = not at all and 4= very much.
|
From beginning of therapy up to completion of therapy
|
Duration of Oral Mucositis
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
Survival analysis was used to estimate the duration of oral mucositis.
Patients were censored if oral mucositis not resolved by the end of the study.
|
From beginning of therapy up to 3 months after completion of therapy
|
Number of Participants With Any Grade Oral Mucositis in Patients Treated to a Cumulative Radiation Dose of at Least 5000 cGy
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
Grade of oral mucositis assessed using the NCI CTCAE version 4.0
|
From beginning of therapy up to 3 months after completion of therapy
|
Number of Participants With Dysgeusia Assessed by CTCAE v. 4.0
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
Variable is reported on the 1-5 CTCAE scale:
The maximum recorded severity is reported. |
From beginning of therapy up to 3 months after completion of therapy
|
Number of Participants With Dysphagia Assessed by CTCAE v. 4.0 and Diet Assessment
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
Variable is reported on the 1-5 CTCAE scale:
The maximum recorded severity is reported. |
From beginning of therapy up to 3 months after completion of therapy
|
Number of Participants With Pain as Assessed by the Visual Analogue Scale (VAS)
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
Variable is reported on the 1-10 scale Higher values represent a worse outcome The maximum recorded severity is reported
|
From beginning of therapy up to 3 months after completion of therapy
|
Number of Participants With Radiodermatitis Assessed by CTCAE v. 4.0
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
Variable is reported on the 1-5 CTCAE scale:
The maximum recorded severity is reported. |
From beginning of therapy up to 3 months after completion of therapy
|
Number of Participants With Trismus Assessed by Measurement of Interincisal Distance
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
Trismus is defined as a measurement of interincisal distance less than or equal to 30mm.
|
From beginning of therapy up to 3 months after completion of therapy
|
Number of Participants With Xerostomia Assessed by CTCAE v. 4.0
Time Frame: Up to 3 months after completion of therapy
|
Variable is reported on the 1-5 CTCAE scale:
The maximum recorded severity is reported. |
Up to 3 months after completion of therapy
|
Mean Cumulative Radiation Dose at Time of Onset of Severe (CTCAE v. 4.0 Grade 3-4) Oral Mucositis
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
The reported dose is at the first incidence of severe oral mucositis.
|
From beginning of therapy up to 3 months after completion of therapy
|
Time to Onset of Severe (CTCAE v. 4.0 Grade 3-4) Oral Mucositis Following the Initiation of Radiotherapy
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
Survival analysis is used to analyze this endpoint
|
From beginning of therapy up to 3 months after completion of therapy
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of Narcotic Analgesia Use During Treatment
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
From beginning of therapy up to 3 months after completion of therapy
|
|
Number of Participants With Breaks in Treatment
Time Frame: Date of completion of chemoradiation therapy
|
Breaks in treatment defined as one of the following: Missing at least 1 chemotherapy treatment; dose reduction in planned cisplatin administration; OR 3 consecutive days of no radiation therapy secondary to mucositis
|
Date of completion of chemoradiation therapy
|
Percent Change in Body Weight During the Course of Treatment
Time Frame: From date of enrollment until the date of completion of chemoradiation therapy, assessed up to 3 months after completion of therapy
|
The percent change in body weight was computed by subtracting the baseline weight from the weight after completion of treatment and dividing that quantity by the baseline weight.
The confidence interval is estimated using the t distribution.
|
From date of enrollment until the date of completion of chemoradiation therapy, assessed up to 3 months after completion of therapy
|
Number of Participants Who Require Feeding Tube Placement During Treatment (Excluding Patients Who Received a Prophylactic Feeding Tube Prior to the Initiation of Therapy)
Time Frame: At the date of completion of chemoradiation therapy
|
At the date of completion of chemoradiation therapy
|
|
Number of Participants With Severe (CTCAE v. 4.0 Grade 3-4) Oral Mucositis by 5000 and 7000 cGy
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
From beginning of therapy up to 3 months after completion of therapy
|
|
Number of Participants With Severe (CTCAE v. 4.0 Grade 3-4) Oral Mucositis by Schedule of Chemotherapy Given Weekly Versus Every 3 Weeks
Time Frame: From beginning of therapy up to 3 months after completion of therapy
|
From beginning of therapy up to 3 months after completion of therapy
|
|
Time to Reach Planned Dose of Radiation Therapy
Time Frame: From the beginning of therapy up to completion of therapy (9 weeks maximum)
|
Kaplan-Meier methods are used to estimate time until reaching planned dose.
|
From the beginning of therapy up to completion of therapy (9 weeks maximum)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Harold Kim, Barbara Ann Karmanos Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-170 (Other Identifier: Wayne State University/Karmanos Cancer Institute)
- P30CA022453 (U.S. NIH Grant/Contract)
- NCI-2016-00406 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mucositis
-
Salma Hesham ElhoufiRecruitingOral Mucositis (Ulcerative) Due to Radiation | Radiation-Induced Mucositis | Radiation MucositisEgypt
-
Ghada zakiNot yet recruiting
-
Galera Therapeutics, Inc.CompletedRadiation Induced Oral MucositisUnited States, Canada, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnMalignant Neoplasm | Gastrointestinal Mucositis
-
Hadassah Medical OrganizationCompletedChemotherapy Induced MucositisIsrael
-
Air Force Military Medical University, ChinaNot yet recruitingMucositis OralChina
-
University Hospital, ToulouseRecruiting
-
Catalysis SLCompletedMucositis OralRussian Federation
-
Al-Azhar UniversityCompletedStomatitis (Oral Mucositis)Egypt
Clinical Trials on Low Level Laser Therapy
-
Universidade Federal de Sao CarlosConselho Nacional de Desenvolvimento Científico e TecnológicoCompleted
-
University of Nove de JulhoSimone Aparecida Penimpedo Calamita; Fabiana Sarilho de Mendonça; Daniela Aparecida... and other collaboratorsCompleted
-
St. Elisabethen Krankenhaus Frankfurt GmbHRecruitingSurgical Scar Tissue of Cesarean Section or Vaginal Tear or EpisiotomyGermany
-
University of BergenCompleted
-
University of BergenNorwegian Fund for Postgraduate Training in PhysiotherapyCompleted
-
Universidade Federal de Sao CarlosFundação de Amparo à Pesquisa do Estado de São Paulo; Faculty of Medicine of... and other collaboratorsCompleted
-
University of OttawaBioFlexTM Laser TherapyCompletedProvoked VestibulodyniaCanada
-
NYU Langone HealthCompleted
-
Universidade do Vale do SapucaiCompletedBreast Neoplasms | Radiotherapy; Adverse Effect, Dermatitis or EczemaBrazil
-
University of Nove de JulhoConselho Nacional de Desenvolvimento Científico e TecnológicoNot yet recruitingPain, Postoperative | Endodontically Treated Teeth